rss
Ann Rheum Dis doi:10.1136/ard.2006.065441

Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: Efficacy in joint and ocular disease

  1. Srilakshmi M Sharma (s_m_sharma{at}yahoo.com)
  1. University Department of Ophthalmology, Bristol Eye Hospital, United Kingdom
    1. Athimalaipet V Ramanan (athimalaipet.ramanan{at}nbt.nhs.uk)
    1. North Bristol NHS Trust & Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
      1. Philip Riley (philip.riley{at}nbt.nhs.uk)
      1. North Bristol NHS Trust & Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
        1. Andrew D Dick (a.dick{at}bristol.ac.uk)
        1. University Department of Ophthalmology, Bristol Eye Hospital, United Kingdom
          • Published Online First 14 December 2006

          Abstract

          There is an identified disparity between the efficacy of TNF ( tumor necrosis factor) inhibition in the treatment of uveitis in paediatric onset inflammatory arthritis and that of joint disease (1,2,3,4,5).

          We retrospectively reviewed the case notes of 6 patients with aggressive, refractory joint and ocular paediatric- onset disease treated with infliximab in a multi- disciplinary clinic. Our report utilizes the Standardised Uveitis Nomenclature (SUN) grading system (6) for uveitis and steroid dose as an outcome measure. All patients received infliximab infusions at weeks 0, 2, 6 and 8 weekly.

          Register for free content

          The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

          Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.